While the drug is not a cure, researchers say it could meaningfully improve both the length and quality of life for patients with advanced disease. | World News

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the buzz it created among ASCO Annual Meeting…

RASolute 302 findings herald a new standard of care in previously treated patients

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.

Daraxonrasib has been hailed as ‘landscape-changing’ for people with the disease

Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancer

Doctors today hailed a breakthrough in the fight against pancreatic cancer after a new drug was shown to give patients precious extra months of life.

New research shows a novel pill is helping people with advanced pancreatic cancer live longer

When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints…

Prostate cancer patients normally have a devastatingly short life expectancy - but the new daily pill being offered in clinical trials could change that

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for…

A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types…

An experimental drug for advanced pancreatic cancer significantly extended survival in a major clinical trial, offering fresh hope for improved treatment...

The results of a clinical trial of a new drug could signal a breakthrough in treating pancreatic cancer

A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types…

Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumours will be next.